PR Newswire Clinical TrialsOriginal article
NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada
NDA FilingPositive
AI Analysis
Summary
NeuroSense Therapeutics completed the Health Canada pre-NDS (New Drug Submission) process for its ALS treatment with regulatory alignment achieved, advancing toward a planned December 2026 filing.
Outcome Details
Completed PrimeC Pre-NDS Process with alignment from Health Canada on planned submission content and structure
Importance:6/10
Sentiment:
0.60
regulatoryALSHealth CanadaNDS filingpre-submission meeting
Read the original article
Published by PR Newswire Clinical Trials on August 6, 2026 3:29 PM